Thr1041
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr1041  -  LATS2 (human)

Site Information
EHAFyEFtFRRFFDD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 31843001

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 4 ) , mutation of modification site ( 4 ) , phospho-antibody ( 3 , 4 ) , western blotting ( 3 , 4 )
Disease tissue studied:
breast cancer ( 4 ) , colorectal cancer ( 4 ) , colorectal carcinoma ( 4 ) , lung cancer ( 4 ) , non-small cell lung cancer ( 4 ) , non-small cell lung adenocarcinoma ( 4 ) , OSCC ( 3 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on LATS2:
activity, induced ( 3 )
Effects of modification on biological processes:
signaling pathway regulation ( 3 , 4 )

References 

1

Li J, et al. (2021) Mechanosensitive turnover of phosphoribosyl pyrophosphate synthetases regulates nucleotide metabolism. Cell Death Differ
34465890   Curated Info

2

Kim E, et al. (2020) -GlcNAcylation on LATS2 disrupts the Hippo pathway by inhibiting its activity. Proc Natl Acad Sci U S A 117, 14259-14269
32513743   Curated Info

3

Nozaki M, et al. (2019) LATS1/2 kinases trigger self-renewal of cancer stem cells in aggressive oral cancer. Oncotarget 10, 1014-1030
30800215   Curated Info

4

Mohseni M, et al. (2014) A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nat Cell Biol 16, 108-17
24362629   Curated Info